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Abstract
Visceral leishmaniasis and HIV co-infection presents diagnostic, monitoring and
treatment challenges. We report a co-infected patient who developed multiple
complications and treatment side-effects, including renal and liver failure, pancytopenia
2with recurrent sepsis along with anal cancer, depression and poor quality-of-life spanning
over two decades. Urgent research specific to this cohort is needed.
Introduction
Leishmaniasis is a vector-borne disease transmitted by sandflies with three well-
recognised clinical syndromes: visceral, mucosal and cutaneous. Visceral Leishmaniasis
(VL), or kala-azar, is transmitted by parasites of the Leishmania donovani complex and
leads to approximately 500,000 new diagnoses each year, 90% of these in India,
Bangladesh, Ethiopia, Sudan, Kenya & Brazil1. Untreated, VL is almost universally fatal1.
Early in the HIV epidemic, VL was recognised as an opportunistic infection in
patients in Southern Europe1-3. Most patients develop clinical features of visceral
leishmaniasis when CD4+T-cell counts are <200cells/μL. As visceral leishmaniasis is not 
classified as a Category C disease4 it is likely to have been underreported. Data on
incidence and prevalence of co-infection is lacking but indicates HIV infection increases
the risk of developing visceral leishmaniasis by >100 fold in endemic countries4. Incidence
appears to have declined in Southern Europe since widespread use of combination
antiretroviral therapy (cART)1-5.
Both HIV and visceral leishmaniasis target key effector immune cells;1-3 death
ensues from secondary bacterial infections, malnutrition, anaemia or haemorrhage1. Host
immunocompetence determines clinical manifestations and in most HIV-infected patients
represents reactivation of latent leishmania1,3,4. cART-induced immune restoration, a key
3component of treatment, may allow withdrawal of anti-leishmania therapy. However,
even with ‘adequate’ immune restoration, relapse is common2-3. Overall, treatment-
response in the HIV setting is suboptimal compared with the mono-infection setting2 and
suppression of clinically active disease rather than cure is the therapeutic goal4.
Case Report
A Caucasian male was diagnosed with HIV-1 infection in 1985, aged 27 years.
During the 1990’s his HIV-infection was treated with dual therapy, zidovudine plus
didanosine. In 1996, after presenting with hepatosplenomegaly and deranged liver
function, visceral leishmaniasis was confirmed on bone marrow biopsy, later speciated as
Leishmania infantum6. The diagnosis coincided with a drop in CD4+T-cells to 90cells/μL 
and was presumed reactivation from childhood exposure in Greece. In 1996, he
commenced protease inhibitor-based (PI) cART and maintained HIV virologic suppression
thereafter. His absolute CD4+T-cell count remained suboptimal and low at between 100-
250 cells/L(15%), presumably secondary to splenic consumption. Antiretroviral switches
were undertaken as new agents became available to reduce the pill burden and risk of
overlapping toxicities and drug-drug interactions.
The patient was treated for visceral leishmaniasis, in the context of HIV co-
infection, with cyclical induction-maintenance with Intravenous (IV)) antimonial agents,
the standard of care at that time, first, sodium stibogluconate (standard weight based
dosing of 20mg/Kg/day), then meglumine antimoniate (20mg/Kg/day) which was sourced
from Brazil. A trial of miltefosine monotherapy in the early 2000s, in an endeavour to
relieve the patient of the burden of long-term parenteral therapy, led to rapid clinical
4failure. Miltefosine was sourced, pre licensure, from Germany under a special
compassionate access program. Subsequently he received monthly cycles of IV liposomal
amphotericin B, however due to quality-of-life concerns he resumed maintenance
therapy with IV meglumine antimoniate.
The nodular lesions he developed on his head and ear in 2003 correlated with an
improvement in clinical and haematological parameters and were thought to represent
an Immune reconstitution inflammatory syndrome (IRIS) and in this setting, a form of
post Kala-azar dermal leishmaniasis6. They resolved with topical paromomycin and
continued leishmania maintenance therapy with meglumine.
In 2004, he was diagnosed with non-cirrhotic portal hypertension, splenomegaly
and varices manifesting with gastrointestinal bleeds. Aetiology of the former was unclear,
but exposure to didanosine probably played a role. Later that year, he developed Listeria
monocytogenes bacteraemia. In 2008, after bone marrow biopsy indicated relapse, he
underwent re-induction with several weeks of daily IV liposomal amphotericin plus oral
posaconazole and was subsequently maintained on monthly IV pentamidine with daily
posaconazole. The latter was sought through compassionate access for off license use.
Anal squamous cell carcinoma was diagnosed and successfully treated in 2009 however
ongoing per-rectal bleeding, post-radiation anal stenosis and chronic severe pain
prompted colostomy formation.
From 2011 until his demise in 2013, he developed repeated sepsis episodes and
progressive pancytopenia. Exacerbations of renal failure precluded adequate
5leishmaniasis treatment. His pre-morbid condition included catastrophic leg cellulitis
(Figure 1a) with Escherichia coli, Enterococcus spp and biopsy confirmed L. infantum
(Figure 1b) which failed to respond to aggressive antibiotic therapy, wound debridement
and skin grafting.
Case Discussion
Clinical diagnosis in HIV co-infected patients is complex. Symptoms can be
atypical, in particular increased gastrointestinal symptoms including diarrhoea and less
frequent splenomegaly, though most patients do present with pancytopenia and fever
and lethargy1,2,4. Concurrent opportunistic infections may confound clinical
appearances4; clinicians need to have a high index of suspicion, particularly in patients
from an endemic region. Parasitological diagnosis remains the gold standard. Speciation
is important, but the PCR molecular test we used to speciate was an ‘in-house’ assay and
thus not validated. Splenic aspiration is used for monitoring disease burden/activity2,4,
however safety concerns precluded this in our patient with monitoring restricted to
clinical assessment, blood parameters and repeated bone marrow aspiration. Using a
combination of serologic and molecular tests improves sensitivity, however further
research is required to determine the value in both screening and diagnosis2,7.
An ongoing challenge remains the paucity of randomised control trial data with
results derived from the mono-infected extrapolated with mixed findings4. Whilst
pentavalent antimonials for HIV-visceral leishmaniasis have fallen from favour due to
toxicities and clinical failure, they remain the mainstay of treatment due to cost and
access constraints, especially in low income countries with the highest burden of disease.
6Liposomal amphotericin B has found increasing utility, however it has been shown to be
comparatively less efficacious in the HIV-infected population1,2,4,8.
Importantly, and a lesson already learned in the HIV setting, is the inherent
danger of sequential monotherapy. Focus is shifting towards combination therapy with
promising data on single dose liposomal amphotericin with miltefosine in the HIV-
negative cohort9. A phase 3 clinical trial is recruiting in Ethiopia to study AmBisome©
monotherapy vs. AmBisome© & miltefosine in HIV-positive patients
(ClinicalTrials.gov:NCT02011958)10. This combination approach has been replicated in a
recently published retrospective Indian study, where co-infected patients were followed
up at 18 months after treatment with 6 infusions of AmBisome© (each dose 5mg/Kg;
cumulative dose 30mg/Kg) and 14 days of miltefosine11. While results were promising,
the overall relapse rates and all-cause mortality (16.6% at 18 months) were far higher
than in mono-infected patients given lower doses of liposomal amphotericin (cumulative
dose of 20mg/Kg).
Recently published data from Ethiopia studying secondary prophylaxis in co-
infected patients on cART with monthly pentamidine also shows improved relapse
rates12. With regards to the triazoles, oral posaconazole has been used to treat cutaneous
L. infantum; there is also promising in-vitro data against L.amazonensis13-14. Further
research is needed.
The current suggested regimen for HIV co-infected patients relies on Liposomal
amphotericin B. Doses and schedules differ depending on the organisation, with doses
7between 2-5mg/kg recommended and daily verses intermittent schedules considered.
Miltefosine is promoted as an alternate or combination agent, though sodium
stibogluconate is still recommended by the World Health Organisation (WHO) as second
line therapy2,15.
cART underpins treatment of HIV-visceral leishmaniasis1,2 but uncertainty remains
regarding timing in relationship to antiprotozoal agents, to avoid IRIS and overlapping
toxicities. Moreover, the exact CD4+T-cell threshold at which anti-leishmania therapy can
safely be withdrawn is unclear. Splenomegaly, leading to low peripheral CD4+T-cell
counts, makes defining CD4+ thresholds harder still. Importantly, immune restoration
may be blunted and relapses still occur despite ‘adequate’ immune restoration3,4.
Ultimately, our patient’s immune failure, recurrent sepsis and renal failure
reduced therapeutic options available for leishmaniasis. Malignancy forced compromised
management. We had no restriction on cART choice so were able to switch away from
ritonavir-boosted PI to minimise drug-drug interactions and avoid drugs that might
compound haematological manifestations and renal toxicities of active visceral
leishmaniasis and or its treatment.
Despite excellent resources, our patient succumbed to complications from chronic
HIV-visceral leishmaniasis co-infection. The case illustrates challenges faced in the real-
life management in a resource rich setting, and emphasises gaps in knowledge. Visceral
Leishmaniasis is a WHO neglected tropical disease3 and as such new drugs need to be
developed. Data specific to co-infected patients is urgently needed. These therapeutic
8advances must be coupled with improved methods to diagnose and monitor disease
activity without requiring invasive tests. As the burden of disease is predominantly in
resource-poor countries, these modalities must be available at affordable prices.
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Figure 1a: Left leg cellulitis with Escherichia coli and Enterococcus spp. growth.
Figure 1b: Left leg biopsy site, confirming L .infantum.
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